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diseases (syphilis, malaria, tuberculosis and bacterial pneumonia)
in developing countries could preventmore than 1.2million deaths
annually. In resource-limited settings, laboratory medicine is still
one of themost neglected pillars of the health care. In such settings,
primary health care services largely depend on diagnostic point of
care testing; therefore the beneﬁts need to overweight the costs.
To optimise the diagnostic point-of-care, there is a need for strict
evaluation focused on relevant clinical outcomes and operational
costs and these evaluations differ from the conventional tests.
However, there is no consistent, standardized approach to assess
the point-of-care testing technologies in resource-limited settings.
Diagnostic point-of-care testing possesses signiﬁcant importance
in infections like TB or HIV, because it eliminates the long turn-
around times and delays and the resulting loss of patients from
the testing and therapy pathway. An ideal rapid diagnostic point-
of-care test used in resource-limited settings should fulﬁl the
following criteria: allowing a quick clinical decision, can be used
by a health careworker (possibly by a nonprofessional), affordable,
rapid, acceptable test efﬁcacy, and cost effectiveness.
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Abstract: Migrant Crisis in Europe 2015 had two major routes,
Balkan route via Greece, Hungary, Austria to Germany and African
route with mainly economic refugees and migrants via Mediter-
ranean Malta Lampedusa, Sicily to continental Italy, France, Spain
and UK. Here we present ﬁrst data on migrant health of the Balkan
route from September to October 2015.
About 316 000 political and humanitarian refugees, 95% from
Syria, Iraq and Afganistan passed through checkpoint Hegye-
shalom, Nickelsdorf 50 km east from Vienna and 10 km from
Bratislava, between September 6th andOctober 20th.Most of them
were healthy young peoplewith children, about 10 percent sick per
transport, in 97 trains from Zakanyi Croatian Boundary or Röszke,
HU- Serbian Boundary to Hegyeshalom, Nickelsdorf HU, AT check-
point. Sick patient’s reported themselves to the symptomatic ﬁeld
heath center with 8-12 HC Tropicteam staff serving in 5 languages.
In RTI patients, nasal/tonsil swabs was taken to Mueller Hinton
agar and transported toNational referenceLaboratory forATB resis-
tance, Nitra, SK.
No major tropical diseases were noted, no case of malaria or
leishmaniasis was detected. Even less cases of emerging ID includ-
ing HIV and tuberculosis were detected as well. Majority of ID
included pneumonia upper respiratory tract infections, skin and
soft tissue infections, scabies, few cases (<3%) of diarrhoea but no
case of cholera have been observed in described period. Among
acute cases, diabetic coma, myocardial infarction, hypertension
crisis and has been noted. From 155 positive results from bacteri-
ology from migrants, only 2 MRSA strains and 3 penicillin resistant
pneumococci were obtained, the rest was commensal bacterial
ﬂora and Candida albicans.
Balkan route in refugee crisis in 2016 in Europe from Syria,
Iraq does not represent major health threat to continental EU, only
few cases of transmissible diseases were noted and an absence of
tropical diseases, multiresistant pathogens and no outbreaks were
observed within ﬁrst 2 months of exodus. Only few MRSA and
penicillin resistant strains from patients from upper and lower res-
piratory tract infections were isolated. Spectrum of diagnoses was
similar to surrounding Slovak, Hungarian and Austrian population
of that EU region.
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Background: Visceral leishmaniasis (VL), or Kala-Azar is a life-
threatening systemic infection caused by protozoan Leishmania,
with sandﬂies as its vectors affecting thepoorest of thepoorpeople.
Indiabears50%of globalVLburdenandwascommitted toeliminate
VL elimination by 2015. New treatment modalities were proposed
by WHO since 2010, yet ﬁrst line treatment in India has remained
unchanged since 2006. The 2014 release of India National Road
Map of Kala azar Elimination marked a milestone in the progress
towards the elimination goal: Single Dose liposomal amphotericin
B (Ambisome®) or SDA was adopted in the national programme.
Role of evidence in the policy change is explored.
Methods & Materials: Médecins Sans Frontières (MSF) started
a VL treatment programme in Bihar, India since 2007, using 20
mg/kg intravenous Ambisome and treated over 11,000 patients
with excellent results. With lack of high quality evidence, a phase
4 trial of new treatmentmodalities including SDAwas commenced
inAugust 2012byMSF, Drug forNeglecteddisease initiative (DNDi)
andRajendraMemorial research Institute (RMRI). Effectiveness and
safety data presented in December 2013. Additionally, a qualitative
study to determine patient perspectives of these new treatments
was conducted. At the same time, advocacywise, a successful nego-
tiation with Gilead as Ambisome producer has led to free donation
of the drug to the Indian Government, further facilitating the pro-
cess towards policy change.
Results: By supporting MoH facilities in implementing alterna-
tive regimen such as Ambisome, MSF demonstrated its feasibility
at different level of health care, including primary health centres.
Evidence from formal trial is indispensable; however, debunking
the perception that such a ‘complex’ treatment could not be imple-
mented as ﬁrst line treatment was as important. Various factors
